Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $430,960.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 5,387 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $80.00, for a total transaction of $430,960.00. Following the completion of the transaction, the insider directly owned 13,320 shares in the company, valued at approximately $1,065,600. The trade was a 28.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $127,200.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $73.86, for a total value of $339,829.86.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $90.78 on Friday. Tarsus Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $91.53. The business has a 50-day simple moving average of $66.01 and a 200 day simple moving average of $65.93. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of -83.28 and a beta of 0.54.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The business had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of research analyst reports. Mizuho decreased their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Jefferies Financial Group upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday. Guggenheim reduced their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. HC Wainwright restated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $90.50.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Tarsus Pharmaceuticals by 5.6% during the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after acquiring an additional 127,470 shares during the period. TimesSquare Capital Management LLC increased its stake in Tarsus Pharmaceuticals by 24.3% in the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock worth $27,221,000 after purchasing an additional 64,941 shares during the period. Bank of America Corp DE lifted its position in Tarsus Pharmaceuticals by 57.5% in the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after purchasing an additional 436,271 shares during the last quarter. Ishara Investments LP bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $1,965,000. Finally, Emerald Investment Advisers LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $3,760,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
• Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
• Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
• Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
• Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.